- Home
- HPP vs NUVB Comparison
HPP vs NUVB Comparison
Compare HPP & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- NUVB
- Stock Information
- Founded
- HPP 1997
- NUVB 2018
- Country
- HPP United States
- NUVB United States
- Employees
- HPP N/A
- NUVB N/A
- Industry
- HPP Real Estate
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- NUVB Health Care
- Exchange
- HPP Nasdaq
- NUVB Nasdaq
- Market Cap
- HPP 1.0B
- NUVB 1.1B
- IPO Year
- HPP 2010
- NUVB N/A
- Fundamental
- Price
- HPP $2.58
- NUVB $3.64
- Analyst Decision
- HPP Hold
- NUVB Strong Buy
- Analyst Count
- HPP 10
- NUVB 7
- Target Price
- HPP $3.10
- NUVB $8.43
- AVG Volume (30 Days)
- HPP 4.3M
- NUVB 6.7M
- Earning Date
- HPP 11-05-2025
- NUVB 11-05-2025
- Dividend Yield
- HPP N/A
- NUVB N/A
- EPS Growth
- HPP N/A
- NUVB N/A
- EPS
- HPP N/A
- NUVB N/A
- Revenue
- HPP $792,977,000.00
- NUVB $14,355,000.00
- Revenue This Year
- HPP N/A
- NUVB $291.13
- Revenue Next Year
- HPP $6.87
- NUVB $332.00
- P/E Ratio
- HPP N/A
- NUVB N/A
- Revenue Growth
- HPP N/A
- NUVB 900.35
- 52 Week Low
- HPP $1.78
- NUVB $1.54
- 52 Week High
- HPP $5.02
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- HPP 40.17
- NUVB 59.23
- Support Level
- HPP $2.51
- NUVB $3.55
- Resistance Level
- HPP $2.79
- NUVB $3.88
- Average True Range (ATR)
- HPP 0.11
- NUVB 0.24
- MACD
- HPP -0.02
- NUVB -0.01
- Stochastic Oscillator
- HPP 20.83
- NUVB 67.02
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.